Sunshine Biopharma Collaborates For Its Lead mRNA-Based Cancer Program

Sunshine Biopharma Inc SBFM has entered into a collaboration agreement with a North American lipid nanoparticle (LNP) company to advance the development of its mRNA-based anticancer macromolecule, K1.1.
The company's collaboration partner will prepare two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma's in-house developed antineoplastic mRNA, K1.1.
Sunshine Biopharma previously showed that its K1.1 mRNA could destroy cancer cells in vitro, including multidrug-resistant breast, ovarian adenocarcinoma, and pancreatic cancer cells.
Also Read: EXCLUSIVE: Sunshine Biopharma Acquires Canadian Generic Player For $22M
Parallel studies using normal human cells showed that K1.1 mRNA had little or no cytotoxic effects.
The partner-generated K1.1a::LNP and K1.1b::LNP will be used to conduct in vivo studies on xenograft mice expressing the in vitro tested human cancers and liver cancer.
The company can rapidly advance to conducting human trials if these mice studies prove successful. The LNP-formulated K1.1 mRNA can be readily adapted for delivery into patients using the mRNA vaccine technology.
Price Action: SBFM shares are down 0.23% at $0.84 on the last check Wednesday.